Onkologische Therapien und Haarverlust

N. Hüttner; C. R. Loehberg; M. P. Lux; M. W. Beckmann

doi:10.1055/s-0032-1327778

Lege artis - Das Magazin zur ärztlichen Weiterbildung, Inhaltsverzeichnis

Geburtshilfe Frauenheilkd 2012; 72(10): R47-R62
DOI: 10.1055/s-0032-1327778

GebFra-Weiterbildung | Refresher

Georg Thieme Verlag KG Stuttgart · New York

Onkologische Therapien und Haarverlust

Autor*innen

N. Hüttner

¹Frauenklinik des Universitätsklinikums Erlangen
C. R. Loehberg

¹Frauenklinik des Universitätsklinikums Erlangen
M. P. Lux

¹Frauenklinik des Universitätsklinikums Erlangen
M. W. Beckmann

¹Frauenklinik des Universitätsklinikums Erlangen

Abstract

Volltext

Referenzen

Literatur
1 McGarvey EL, Leon-Verdin M, Baum L et al. An evavluation of a computer imaging program to prepare women for chemotherapy-related alopecia. Psycho-Oncology 2010; 19: 756-766
2 Mols F, van den Hurk CJ, Vingerhoets JJM et al. Scalp cooling to prevent chemotherapy-induced hair loss: practical and clinical considerations. Support Care Cancer 2009; 17: 181-189
3 Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psycho-Oncology 2008; 17: 317-328
4 Batchelor D. Hair and cancer chemotherapy: consequences and nursing care – a literature study. Eur J Cancer Care (Engl ) 2001; 10: 147-163
5 McElwee KJ, Shapiro J. Promising therapies for treating and/or preventing androgenic alopecia. Skin Therapy Lett 2012; 17: 1-4
6 McGarvey EL, Baum LD, Pinkerton RC et al. Psychological sequelae and alopecia among women with cancer. Cancer Pract 2001; 9: 283-289
7 Roe H. Chemotherapy-induced alopecia: advice and support for hair loss. Br J Nurs 2011; 20: 4-11
8 Trueb RM. Chemotherapy-induced alopecia. Curr Opin Support Palliat Care 2010; 4: 281-284
9 Wang J, Lu Z, Au JL. Protection against chemotherapy-induced alopecia. Pharm Res 2006; 23: 2505-2514
10 Chon SY, Champion RW, Geddes ER et al. Chemotherapy-induced alopecia. J Am Acad Dermatol 2011; 67: e37-e47
11 Trueb RM. Chemotherapy-induced hair loss. Skin Therapy Lett 2010; 15: 5-7
12 Alonso E, Fuchs E. The hair cycle. J Cell Sci 2006; 119: 391-393
13 Ohnemus U, Uenalan M, Inzunza J et al. The hair follicle as an estrogen target and source. Endocr Rev 2006; 27: 677-706
14 Stenn KS, Paus R. Controls of hair follicle cycling. Physiol Rev 2001; 81: 449-494
15 Röcken M et al. Taschenatlas Dermatologie. Stuttgart: Thieme Verlag; 2010: 11
16 Sterry W et al. Kurzlehrbuch Dermatologie. Stuttgart: Thieme Verlag; 2011: 243
17 Otomo S. Hair growth effect of minoxidil. Nihon Yakurigaku Zasshi 2002; 119: 167-174
18 Botchkarev VA. Molecular mechanisms of chemotherapy-induced hair loss. J Investig Dermatol Symp Proc 2003; 8: 72-75
19 Paus R. Principles of hair cycle control. J Dermatol 1998; 25: 793-802
20 Yeager CE, Olsen EA. Treatment of chemotherapy-induced alopecia. Dermatol Ther 2011; 24: 432-442
21 Tallon B, Blanchard E, Goldberg LJ. Permanent chemotherapy-induced alopecia: case report and review of the literature. J Am Acad Dermatol 2009; 10: 333-336
22 Van den Hurk CJ, Mols F, Vingerhoets JJM et al. Impact of alopecia and scalp cooling on the well-being of breast cancer patients. Psycho-Oncology 2010; 19: 701-709
23 Imanishi H, Tsuruta D, Tateishi C et al. Laminin-511, inducer of hair-growth, is down-regulated and its suppressor in hair growth, laminin-322 up-regulated in chemotherapy-induced alopecia. J Dermatol Sci 2010; 58: 43-54
24 Hesketh PJ, Batchelor D, Golant M et al. Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer 2004; 12: 543-549
25 Im Internet: http://www.fachinfo.de Stand: 17.5.2012
26 Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. 2012 Im Internet: http://www.krebsgesellschaft.de/download/S3_Brustkrebs_Update_2012_OL_Langversion.pdf Stand: 17.5.2012
27 Gateley CA, Bundred NJ. Alopecia and breast disease. BMJ 1997; 314 (7079) 481
28 Jamin C. Androgenetic alopecia. Ann Dermatol Venereol 2002; 129 (5 Pt 2) 801-803
29 Li W, Li C, Lu Z. Vascular endothelial growth factor and its receptors my be one mechanism for androgenetic alopecia. Med Hypotheses 2009; 72: 366-367
30 Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest 2001; 107: 409-417
31 Conrad F, Paus R. Estrogens and the hair follicle. JDDG 2004; 2: 412-423
32 Ehmann LM, Heinemann V, Wollenberg A. Neue Tyrosinkinase- und EFGR-Inhibitoren in der Tumortherapie. Herz und Haut als wichtige Schädigungsorgane. Teil B: Haut. Internist 2011; 52: 1359-1364
33 Boehm S, Rothermundt C, Hess D et al. Antiangiogenic drugs in oncology: a focus on drug safety and the elderly – a mini review. Gerontology 2010; 56: 303-309
34 Molina MA, Codony-Servat J, Albanell J et al. Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61: 4744-4749
35 Baselga J, Cortés J, Kim SB et al. Pertuzumab plus Trastuzumab plus Docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119
36 Mokbel K, Hassanally D. From HER2 to herceptin. Curr Med Res Opin 2001; 17: 51-59
37 Zander T, Hallek M. Thyrosinkinaseinhibitoren in der Onkologie. Internist 2011; 52: 595-600
38 Rosman IS, Anadkat MJ. Tufted hair folliculitis in a woman treated with trastuzumab. Target Oncol 2010; 5: 295-296
39 Scheuer W, Friess T, Burtscher H et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009; 69: 9330-9336
40 Franklin MC, Kendall DC, Vajdos FF et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5: 317-328
41 Im Internet: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm307592.htm Stand: 17.5.2012
42 Im Internet: http://www.ema.europa.eu Stand: 17.5.2012
43 Affara NI, Trempus CS, Schanbacher BL et al. Activation of Akt and mTOR in CD34+/K15+keratinocyte stem cells and skin tumors during multi-stage mouse skin carcinogenesis. Anticancer Res 2006; 26: 2805-2820
44 Perez EA, Spano JP. Current and emerging targeted therapies for metastatic breast cancer. Cancer 2012; 118: 3014-3025
45 Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-529
46 Lee WJ, Lee JL, Chang SE et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. BJD 2009; 161: 1045-1051
47 Anderson JE, Hunt JM, Smith IE. Prevention of doxorubicin-induced alopecia by scalp cooling in patients with advanced breast cancer. Br Med J (Clin Res Fd) 1981; 282: 423-424
48 Grevelman EG, Breed WPM. Prevention of chemotherapy-induced hair loss by scalp cooling. Ann Oncol 2005; 16: 352-358
49 Hussein AM. Chemotherapy-induced alopecia: new developments. South Med J 1993; 86: 489-496
50 Poder TG, He J, Lemieux R. Effectiveness of scalp cooling in chemotherapy. Bull Cancer 2011; 98: 1119-1129
51 Van den Hurk CJ, Peerbooms M, Van de Poll-Franse LV et al. Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients – results of the Dutch Scalp Cooling Registry. Acta Oncol 2012; 51: 497-504
52 Auvinen PK, Mähönen UA, Soininen KM et al. The effectiveness of a scalp cooling cap in preventing chemotherapy-induced alopecia. Tumori 2010; 96: 271-275
53 Lemieux J, Amireault C, Provencher L et al. Incidence of scalp metastase in breast cancer: a retrospective cohort study in women who were offered scalp cooling. Breast Cancer Res Treat 2009; 118: 547-552
54 Van de Sande MA, van den Hurk CJ, Breed WP et al. Allow scalp cooling during adjuvant chemotherapy in patients with breast cancer; scalp metastases rarely occur. Ned Tijdschr Geneeskd 2010; 154: A21-A34
55 Lachgar S, Charveron M, Gall Y et al. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol 1998; 138: 407-411
56 Rossi A, Cantisani C, Melis L et al. Minoxidil use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov 2012; 6: 130-136
57 Chen G, Baechle A, Nevins TD et al. Protection against cyclophosphamid-induced alopecia and inhibition of mammary tumor growth by topical 1,25-Dihyroxyvitamin D3 in mice. Int J Cancer 1998; 75: 303-309
58 Peters EMJ, Foitzik K, Paus R et al. A new strategy for modulating chemotherapy-induced alopecia, using PTH/PTHrP receptor agonist and antagonist. J Invest Dermatol 2001; 117: 173-178
59 Katikaneni R, Ponnapakkam T, Suda H et al. Treatment for chemotherapy-induced alopecia in mice using parathyroid hormone agonists and antagonists linked to a collagen binding domain. Int J Cancer 2011; 131: E813-E821
60 Münstedt K, Manthey N, Sachsse S et al. Changes in self-concept and body image during alopecia induced cancer chemotherapy. Support Care Cancer 1997; 5: 139-143
61 World Health Organization. WHO Handbook for reporting results of cancer treatment. Geneva: World Health Organization; 1979. Im Internet: http://whqlibdoc.who.int/offset/WHO_OFFSET_48.pdf Stand 17.5.2012
62 NCI-CTAE Version 4.0. Im Internet: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14.xls Stand 21.9.2012